Analytical Data
-
Gene name
PFS230
- Application
-
Alternative Names
PFS230；PF230；S230；Gametocyte surface Protein P230
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P68874
-
Expression Region
2980-3116aa
-
AA Sequence
YKEIHGCDFTGKYSHLFTYSKKPLPNDDDICNVTIGNNTFSGFACLSHFELKPNNCFSSVYDYNEANKVKKLFDLSTKVELDHIKQNTSGYTLSYIIFNKESTKLKFSCTCSSNYSNYTIRITFDPNYIIPEPQSRA
-
Molecular Weight
15.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PFS230 is a recombinant protein derived from the Plasmodium falciparum, the parasite responsible for the most severe form of malaria. The research surrounding PFS230 focuses on its role as a putative target for malaria vaccine development, particularly in the context of blocking transmission from mosquitoes to humans. This protein is expressed in the sexual stages of the parasite, specifically in the gametocytes, and is crucial for the formation of zygotes within the mosquito's midgut. Understanding the structure and function of PFS230 is vital for the design of immunological strategies aimed at eliciting a robust immune response that could inhibit the transmission cycle. Recent studies have highlighted PFS230 as a promising candidate for inclusion in multi-component vaccine formulations due to its capacity to trigger anti-gametocyte immune responses. Additionally, advancements in recombinant DNA technology have facilitated the large-scale production of PFS230, enabling extensive immunological studies. As malaria remains a significant global health challenge, targeting proteins like PFS230 represents a strategic approach to reducing transmission rates and potentially contributing to malaria eradication efforts. Consequently, ongoing research aims to elucidate the immunogenic properties of PFS230, assess its efficacy in animal models, and explore its potential co-administration with other malaria antigens to enhance vaccine efficacy. Overall, the investigation into PFS230 exemplifies the critical intersection of molecular biology, immunology, and public health in the fight against malaria.
